Can lower doses of immunotherapy be safer without losing effectiveness?
NCT ID NCT07174453
First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times
Summary
This study looks at whether giving a lower dose of immunotherapy (pembrolizumab or nivolumab) causes fewer serious side effects than the standard higher dose. About 192 adults with solid tumors will be randomly assigned to receive either the higher or lower dose. The main goal is to compare the number of severe immune-related side effects between the two groups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The University of Kansas Cancer Center
RECRUITINGWestwood, Kansas, 66205, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a 'Universal' cancer target outsmart resistant blood cancers?
- Can a Cancer-Fighting virus shrink resistant tumors?
- ECMO in kids with cancer: a closer look at survival and risks
- New PET tracer could sharpen cancer detection
- Double-Drug attack on Hard-to-Treat cancers
- Engineered immune cells take on Hard-to-Treat cancers